Karin Jooss, Ph.D., has served as our Executive Vice President and Head of Research and Development since March 2021. Previously, since April 2016, Dr. Jooss had served as our Executive Vice President of Research and Chief Scientific Officer. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss was the Head of Cancer Immuno-Therapeutics in the Vaccine Immuno-Therapeutics Department at Pfizer, Inc., a public pharmaceutical company, where she was also a member of the Vaccine Immuno-Therapeutics Leadership Team and served as Head of the Immuno-Pharmacology Team with responsibilities including Clinical Development. Prior to joining Pfizer, Dr. Jooss served at Cell Genesys, Inc. as Vice President of Research, from June 2005 to April 2009, and as Senior Director of Research, from July 2001 to June 2005. Dr. Jooss is on the Editorial Board of Molecular Therapy and the Journal of Gene Medicine, and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss currently serves on the Board of Directors of Fate Therapeutics, Inc. Dr. Jooss received her diploma in Theoretical Medicine from the University of Marburg in Germany, a Ph.D. in Molecular Biology from the University of Marburg in Germany and performed postgraduate work in Gene Therapy and Immunology at the University of Pennsylvania.